secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2025-07-25T23:59:59+00:00
Accession:  0001193125-25-164789
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio raises $80M equity; Q2 revenue $26.4M (+60% QoQ), ANKTIVA units up 246%
--------------------------------------------------------------------------------

- Registered direct offering of 29.6M shares and warrants at $2.70/unit, gross proceeds ~$80M.
- Q2 2025 revenue $26.4M, up 60% from Q1 2025; year-to-date sales ~$43M.
- Cash and equivalents $153.7M as of June 30, 2025.
- FDA refused to file supplemental BLA for papillary NMIBC; company re-evaluating approach with new data.
- UK MHRA approved ANKTIVA marketing authorization; NSCLC RCT initiated in US.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000119312525164789/0001193125-25-164789-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000119312525164789/d20571d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-164789

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer